← Back to Clinical Trials
Recruiting NCT07139522

Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia

◆ AI Clinical Summary

This study compares two different medications (dexamethasone and magnesium sulfate) added to a numbing agent used during a nerve block procedure to help control pain after cesarean section surgery. The nerve block is performed using ultrasound guidance to numb the area around the spine, and researchers want to see which added medication works better for pain relief after delivery.

Key Objective: This trial is testing whether adding dexamethasone or magnesium sulfate to a spinal nerve block can better reduce pain and improve recovery after cesarean section surgery.

Who to Consider: Women scheduled for elective cesarean section under spinal anesthesia who want to explore options for improved postoperative pain control should consider this trial.

Trial Parameters

Condition Dexamethasone
Sponsor Cairo University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age 35 Years
Start Date 2023-12-01
Completion 2025-12-01
Interventions
BupivacaineDexamethasoneMagnesium sulphate

Brief Summary

This study aims to compare the efficacy of adding dexamethasone and magnesium sulfate as an adjuvant to bupivacaine in bilateral erector spinae block in postoperative pain control in patients undergoing caesarean section under spinal anesthesia.

Eligibility Criteria

Inclusion Criteria: * Age from 18 to 35 years. * Full-term, singleton, pregnant women. * American Society of Anesthesiologists (ASA) physical status II. * Scheduled for elective cesarean delivery under spinal anesthesia. Exclusion Criteria: * Refusal of the patient. * Emergency caesarean sections. * Patients having chronic diseases as asthma, cardiovascular disorders (Significant arrhythmias, Severe Valvular diseases, congenital heart diseases, ischemic heart disease, cardiomyopathy, deep venous thrombosis ,and pulmonary embolism) * Renal impairment (Creatinine level ≥ 2mg/dl, urea ≥ 25mg/dL), liver impairment \[Alanine aminotransferase (ALT) \< 45 U/L, Aspartate aminotransferase (AST) \< 45 U/L\]. * Allergy to the drug enrolled in the study. * Body mass index (BMI) ≥ 35 kg/m2. * Hypertensive disorders of pregnancy. * Contraindication to spinal anesthesia, such as coagulopathy \[platelet count \<150.000, international normalized ratio (INR) \> 1.2\], or local infection. * Requirement f

Related Trials